NL-OMON27789Not yet recruitingNot Applicable
Reduce antibiotics use by wait-and-see prescription.
IVM (subsidized by ZonMw)0 sites1,600 target enrollmentStarted: TBDLast updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 1,600
Study Overview
Brief Summary
/A
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •1. All patients who consult their GP with URTI are in principal eligible to receive a wait-and-see prescription. Since, preferably, GPs should not prescribe antibiotics to patients with URTI, in practice only those patients for whom the GP thinks a WASP is an option will receive a WASP and only after discussing it with the patient (note: if the GP thinks the patient needs an antibiotic s/he will prescribe that antibiotic without discussing the principle of WASP). It is up to the GP to discuss a WASP with the patient and to decide whether or not to prescribe a WASP;
- •2. Patients of all ages will be included.
Exclusion Criteria
- Not provided
Investigators
Similar Trials
Recruiting
Not Applicable
Reducing the prescription of antibiotics in newborn infants, suspected for an early onset sepsis.Early onset sepsisNeonatal sepsisCytokinesAntibioticsVroege infectieNeonatale infectieCytokinenAntibioticaNL-OMON22612o sponsor900
Completed
Not Applicable
Decreasing Unnecessary Antibiotics Prescribed for Possible Pneumonia Despite Normal Respiratory Rate and OxygenationPneumoniaNCT05172791Brigham and Women's Hospital643
Recruiting
Not Applicable
Reducing the prescription of antibiotics in newborn infants suspected for having an early onset sepsis.Early Onset SepsisInfection1000401810028920NL-OMON31252niversitair Medisch Centrum Groningen920
Not yet recruiting
Not Applicable
Safe shortening of antibiotic treatment duration for complicated Staphylococcus aureus bacteremiaStaphylococcus aureus bacteremiaNL-OMON28621Amsterdam UMC400
Active, not recruiting
Phase 1
Study to determine optimal duration of antibiotic treatment for Staphylococcus aureus bacteremiaEUCTR2019-004921-25-NLAmsterdam UMC396